Cazzaniga, M, Verusio, C, Ciccarese, M
, Fumagalli, A, Sartori, D, Ancona, C, Airoldi, M, Moretti, G, Ficorella, C, Arcangeli, V, Diodati, L, Zambelli, A, Febbraro, A, Generali, D, Pistelli, M, Garrone, O, Musolino, A
, Vici, P, Maur, M, Mentuccia, L, La Verde, N
, Bianchi, G, Artale, S, Blasi, L
, Piezzo, M, Atzori, F, Turletti, A, Benedetto, C, Cursano, MC, Fabi, A, Gebbia, V, Schirone, A
, Palumbo, R, Ferzi, A, Frassoldati, A, Scavelli, C & Clivio, L 2018, '
Correction: Everolimus (Eve) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9:77 (34639-34640) DOI: 10.18632/oncotarget.25874)',
Oncotarget, vol. 9, no. 77, pp. 34639-34640.
https://doi.org/10.18632/oncotarget.26213